SOURCE: Equity News Circuit

Equity News Circuit

May 24, 2013 08:45 ET

Free Research Reports on CRM, GAME, HIHO and ZIOP Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 24, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country., Inc. (NYSE: CRM) shares traded in the range of $43.02 to $46.05 Thursday before settling to close at $45.69, a decrease of 0.2 percent. The company expects revenues for the second quarter of fiscal 2014 are expected to be in the range of $931 million to $936 million. The average analyst estimate had called for revenues of $934.55 million, according to Thomson Reuters.

Find out more about including full access to the free equity report at:

Shanda Games Limited (NASDAQ: GAME) shares gained 16.08 percent on volume of 5.48 million shares traded Thursday to close at $3.61. The company reported a net income of RMB275.2 million (US$43.9 million) for the first quarter of 2013, an increase of 10.3 percent when compared to the previous quarter.

Find out more about Shanda Games including full access to the free equity report at:

Highway Holdings Ltd. (NASDAQ: HIHO) shares surged 31.58 percent on volume of 1.65 million shares traded to close at $2.25. The company announced that it has received a multi-year order for vacuum cleaner components worth approximately $400,000 a year. Shares of Highway Holdings are up approximately 19 percent year-to-date.

Find out more about Highway Holdings including full access to the free equity report at:

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) shares gained 18.13 percent on volume of 2.54 million shares traded to close at $2.02. The company is scheduled to present at the 38th Annual Deutsche Bank Health Care Conference on Wednesday, May 29th. Shares of ZIOPHARM have fallen approximately 51 percent year-to-date.

Find out more about ZIOPHARM Oncology including full access to the free equity report at:

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information